Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

Adoptive T cell therapy (ACT) has yielded high response rates in melanoma, however 50–60% of patients experience no clinical benefit. Here, the authors identify predictive biomarkers, high non-synonymous mutation and high expressed neoantigen load, that associate with clinical benefit in ACT melanom...

Full description

Bibliographic Details
Main Authors: Martin Lauss, Marco Donia, Katja Harbst, Rikke Andersen, Shamik Mitra, Frida Rosengren, Maryem Salim, Johan Vallon-Christersson, Therese Törngren, Anders Kvist, Markus Ringnér, Inge Marie Svane, Göran Jönsson
Format: Article
Language:English
Published: Nature Publishing Group 2017-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-01460-0

Internet

https://doi.org/10.1038/s41467-017-01460-0

Similar Items